Back to Journals » Cancer Management and Research » Volume 7

Treatment of metastatic colorectal cancer: focus on panitumumab

Authors Tay RY, Wong R, Hawkes EA

Received 6 April 2015

Accepted for publication 5 May 2015

Published 24 June 2015 Volume 2015:7 Pages 189—198

DOI https://doi.org/10.2147/CMAR.S71821

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Kenan Onel

Rebecca Y Tay,1 Rachel Wong,1–3 Eliza A Hawkes1,3,4

1Department of Medical Oncology, Eastern Health, Box Hill, VIC, Australia; 2Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; 3Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia; 4Department of Oncology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Heidelberg, VIC, Australia

Abstract: Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

Keywords: panitumumab, metastatic colorectal cancer, KRAS, RAS, EGFR, monoclonal antibody

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine

Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL

Cancer Management and Research 2015, 7:279-289

Published Date: 25 August 2015

Expanding role of lenalidomide in hematologic malignancies

Ghosh N, Grunwald MR, Fasan O, Bhutani M

Cancer Management and Research 2015, 7:105-119

Published Date: 2 May 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010